Myosin Therapeutics is a biopharmaceutical company developing small molecule modulators that target myosin motor proteins to treat glioblastoma and substance use disorders. Their therapies aim to inhibit tumor invasion and proliferation in cancer while regulating actin polymerization in the brain to address the motivation for drug use.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MPFounders
Product
Problem
Glioblastoma, a common and lethal glioma, has a median survival rate of only 15 months despite aggressive treatments like surgery, chemotherapy, and radiotherapy. Similarly, stimulant use disorders, such as methamphetamine use disorder, lack FDA-approved medications, creating a significant unmet need for effective therapies.
Solution
Myosin Therapeutics is developing small molecule modulators targeting myosin motor proteins to address critical unmet needs in oncology and central nervous system disorders. For glioblastoma, their lead candidate, MT-125, is a dual inhibitor of NMIIA and NMIIIB, designed to simultaneously block tumor invasion and proliferation. For substance use disorders, their non-muscle myosin II inhibitors regulate actin polymerization in dendritic spines, which are key to the motivation for drug use. These targeted therapies aim to go beyond symptom relief by directly addressing the root causes of these diseases at the molecular level.
Target Audience
The primary target audience includes patients suffering from glioblastoma and individuals with stimulant use disorders, as well as the healthcare professionals who treat these conditions.
Features
- MT-125: A first-in-class, small molecule selective dual inhibitor of non-muscle myosin (NM) IIA and IIB for glioblastoma treatment.
- MT-110: A non-muscle myosin II inhibitor in development for stimulant use disorders, with a lead indication in Methamphetamine Use Disorder.
- Platform for discovery of novel small molecule modulators for molecular nanomotors.
- GMP drug substance manufacturing campaign completed for MT-125, yielding several kilograms of material.
- FDA Orphan Drug Designation for MT-125 for the treatment of malignant gliomas, providing benefits such as market exclusivity and tax credits.